Applied therapeutics provides regulatory update on galactosemia program

New york, jan. 03, 2022 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update on the at-007 galactosemia program.

APLT Ratings Summary

APLT Quant Ranking